Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
7 Ideal "Safer" Dividend Buys From 61 September Graham Value All-Stars (GVAS)
12:16pm, Tuesday, 30'th Sep 2025
The article analyzes Large Cap Value (GASV) stocks using YCharts' Value Score and the Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Seven of fourteen 'safer' lowest-pr
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Monday, 29'th Sep 2025
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Buy 7 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 September Dividend Dogs
10:10am, Sunday, 28'th Sep 2025
Seven of the top fifteen Barron's Better Bets (BBB) dividend 'dogs' - including CAG, PFE, VZ, BMY, UDR, KIM, and KEY - are attractively priced for income investors. Analyst forecasts project 17.61% to
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
10:41am, Friday, 26'th Sep 2025
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
Bristol Myers to sell psoriasis drug at over 80% discount
07:08am, Thursday, 25'th Sep 2025
Bristol Myers Squibb said on Thursday it will sell its psoriasis drug Sotyktu directly to cash-paying patients at a more than 80% discount to the drug's list price.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu®.
Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note
06:45pm, Wednesday, 24'th Sep 2025
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $44.16, indicating a -1.67% shift from the previous trading day.
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
10:46am, Wednesday, 24'th Sep 2025
Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.
Bristol-Myers Squibb Company (NYSE:BMY ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 23, 2025 9:40 AM EDT Company Participants Lynelle Hoch - Presiden
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies.
Buy Bristol Myers Squibb Stock At $45?
06:55am, Tuesday, 23'rd Sep 2025
Bristol-Myers Squibb (NYSE: BMY) has considerably lagged behind the overall market, with its stock decreasing by 20% this year, while the S&P 500 index has risen by 14%. This drop can be attributed in
1 Reason to Buy Bristol Myers Squibb Stock
03:26am, Tuesday, 23'rd Sep 2025
Investors looking for dividend stocks that offer high yields and steady payout growth keep noticing Bristol Myers Squibb (BMY -0.08%). The pharmaceutical giant's dividend payout has been moving in the
Bristol Myers plans to launch schizophrenia drug in UK at list price equal to the US
07:26am, Monday, 22'nd Sep 2025
Bristol Myers Squibb said on Monday that it plans to launch its schizophrenia treatment Cobenfy in the UK in 2026 at a price that is equal to its US list price.
Bristol Myers Squibb: Buy This Deep Bargain Before The Market Wakes To Income
08:30am, Saturday, 20'th Sep 2025
Bristol Myers Squibb is a deep value opportunity, trading at a forward PE of 7x and offering a 5.5% dividend yield. BMY's next-gen portfolio drives double-digit growth, with blockbuster drugs like Reb
Can Bristol Myers Squibb's Restructuring Program Boost Earnings Growth?
11:15am, Friday, 19'th Sep 2025
Bristol Myers ramps up a $2.5B restructuring plan to cut costs, streamline operations, and offset pressure from generic competition.
